Abstract
<title>Abstract</title> <p>Ovarian cancer remains a leading cause of gynecologic cancer mortality due to late-stage diagnosis and the presence of malignant ascites. Elevated levels of pro-inflammatory cytokines and growth factors in ascites promote tumor progression, angiogenesis, and chemoresistance. Resveratrol, a natural polyphenol with anticancer properties, inhibits pro-inflammatory cytokines and growth factors in various cell types. However, its effects on ascites-derived epithelial ovarian cancer (EOC) cells remain unknown. This study aimed to determine the effect of resveratrol on cytokine and growth factor production in EOC cells isolated from malignant ascites. Primary EOC cells isolated from 11 patients were treated with resveratrol at 6.25 and 12.5 µM for 72 and 144 h. Cell viability and proliferation were determined using trypan blue exclusion and XTT assays, respectively. Interleukin (IL)-1β, IL-6, IL-8, tumor necrosis factor-α (TNF-α), vascular endothelial growth factor (VEGF), epidermal growth factor (EGF), and progranulin (PGRN) levels were quantified by ELISA. Resveratrol did not significantly affect cell viability but significantly reduced cell proliferation in a dose-dependent manner. Resveratrol decreased IL-8 and IL-1β at both concentrations at 72 h, whereas IL-6 showed a non-significant reduction. At 144 h, IL-8 levels remained significantly reduced only at 12.5 µM. Resveratrol also significantly reduced VEGF and PGRN levels at both concentrations at 72h and 144 h. TNF-α and EGF were not detected. These data demonstrate that resveratrol decreases the secretion of pro-inflammatory and angiogenic factors in ascites-derived EOC cells without inducing cytotoxicity, supporting its potential as an adjuvant in ovarian cancer therapy targeting inflammation and angiogenesis.</p>